Ownership Capital B.V. Sells 48,961 Shares of DexCom, Inc. (NASDAQ:DXCM)

Ownership Capital B.V. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,434,774 shares of the medical device company’s stock after selling 48,961 shares during the period. DexCom makes up approximately 4.0% of Ownership Capital B.V.’s investment portfolio, making the stock its 13th largest position. Ownership Capital B.V. owned about 0.37% of DexCom worth $178,041,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in DXCM. Valley National Advisers Inc. boosted its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the period. MV Capital Management Inc. boosted its holdings in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares during the period. Washington Trust Advisors Inc. boosted its holdings in shares of DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares during the period. NBC Securities Inc. bought a new stake in shares of DexCom during the third quarter worth approximately $47,000. Finally, Thompson Siegel & Walmsley LLC bought a new stake in shares of DexCom during the third quarter worth approximately $48,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM traded down $13.67 during trading on Friday, hitting $124.34. 8,578,184 shares of the stock traded hands, compared to its average volume of 2,409,208. The business has a 50 day moving average price of $131.13 and a 200 day moving average price of $118.30. The company has a market cap of $49.24 billion, a price-to-earnings ratio of 80.22, a PEG ratio of 2.37 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.38%. Equities research analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the sale, the chief operating officer now owns 273,913 shares of the company’s stock, valued at $36,816,646.33. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 189,375 shares of company stock worth $25,530,859. Corporate insiders own 0.41% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Canaccord Genuity Group lifted their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday. Finally, Citigroup lifted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $141.67.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.